COMBI — Combigene AB Share Price
Last trade - 00:00- SEK142.96m
- SEK22.46m
- SEK26.70m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.73% | ||
| Return on Equity | -12.34% | ||
| Operating Margin | -108.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.01 | n/a | n/a | 84.04 | 26.7 | n/a | n/a | 54.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Directors
- Arne Ferstad CHM (69)
- Jan Nilsson CEO (70)
- Louise Aspenberg CFO
- Karin Agerman VRD (46)
- Susana Ayesa Alvarez DRC (49)
- Hilde Furberg DRC (63)
- Peter Nilsson DRC (49)
- Lars Thunberg DRC (53)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- October 3rd, 1990
- Public Since
- May 25th, 2015
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 19,801,197
- Address
- Agavagen 52A, LIDINGOE, 181 55
- Web
- https://combigene.com/
- Phone
- +46 406718906
- Auditors
- Mazars SET Revisionsbyra AB
Upcoming Events for COMBI
Similar to COMBI
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 01:05 UTC, shares in Combigene AB are trading at SEK7.22. This share price information is delayed by 15 minutes.
Shares in Combigene AB last closed at SEK7.22 and the price had moved by -16.77% over the past 365 days. In terms of relative price strength the Combigene AB share price has underperformed the FTSE Global All Cap Index by -20.43% over the past year.
There is no consensus recommendation for this security.
Combigene AB does not currently pay a dividend.
Combigene AB does not currently pay a dividend.
Combigene AB does not currently pay a dividend.
To buy shares in Combigene AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK7.22, shares in Combigene AB had a market capitalisation of SEK142.96m.
Here are the trading details for Combigene AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: COMBI
Based on an overall assessment of its quality, value and momentum Combigene AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Combigene AB is SEK2.30. That is 68.14% below the last closing price of SEK7.22.
Analysts covering Combigene AB currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Combigene AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -23.98%.
As of the last closing price of SEK7.22, shares in Combigene AB were trading -10.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Combigene AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK7.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Combigene AB's management team is headed by:
- Arne Ferstad - CHM
- Jan Nilsson - CEO
- Louise Aspenberg - CFO
- Karin Agerman - VRD
- Susana Ayesa Alvarez - DRC
- Hilde Furberg - DRC
- Peter Nilsson - DRC
- Lars Thunberg - DRC